# Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali

> **NCT06080243** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Oxford** · enrollment: 330 (estimated)

## Conditions studied

- Healthy Women of Child Bearing Potential

## Interventions

- **BIOLOGICAL:** R21/Matrix-M1
- **BIOLOGICAL:** Saline and R21/Matrix-M1
- **OTHER:** Sterile isotonic (0.9%) normal saline

## Key facts

- **NCT ID:** NCT06080243
- **Lead sponsor:** University of Oxford
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-03-19
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-12-31
- **Target enrollment:** 330 (ESTIMATED)
- **Last updated:** 2026-02-23

## Collaborators

- Malaria Research and Training Center, Bamako, Mali
- European Vaccine Initiative

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06080243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06080243, "Assessment of Safety, Immunogenicity and Efficacy of R21/Matrix-M1 Malaria Vaccine in Healthy WOCBP in Mali". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06080243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*